Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (1547)	3/10/1999 12:25:00 PM
From: Rob C.	Read Replies (1) \| Respond to of 2539

Wouldn't this be a prelude of things to come??? "Our goal is to bring our already solid DuPont Pharmaceuticals to critical mass through strategic alliances," Holliday said in the statement. "Given the success of our discussions to date, we expect to be able to conclude one or more of these alliances by the end of this year." Investors pushed up DuPont's stock $1.88 to $55.44 in early trade on the New York Stock Exchange. DuPont said it will file to launch the "tracking stock" of its life sciences with the U.S. Securities and Exchange Commission late in 1999, and will seek shareholder approval the following quarter. Tracking stocks are designed to isolate particular assets within a corporation that may have a particular value. Pharmaceuticals typically are far more profitable than chemicals, which for over a century have been the lifeblood of Wilmington, Del.-based DuPont. DuPont signaled its determination last summer to become a major player in life sciences, which includes pharmaceuticals and agricultural products, when it agreed to buy Merck & Co's <MRK.N> 50 percent interest in the two companies' DuPont-Merck joint venture for $2.6 billion. DuPont and Merck continue to share marketing rights on Sustiva, an AIDS drug that is the crown jewel of DuPont's pharmaceuticals portfolio. A published report earlier this month said that DuPont and life sciences heavyweight Monsanto Co <MTC.N> were in preliminary merger talks. Both companies had declined comment. REUTERS Rtr 11:05 03-10-99 Copyright 1999, Reuters News Service Copyright © 1997 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. or such other notice as may be agreed by the parties in writing.